Literature DB >> 7250152

On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.

J Heykants, R Hendriks, W Meuldermans, M Michiels, H Scheygrond, H Reyntjens.   

Abstract

The pharmacokinetics and bioavailability of domperidone, a novel gastrokinetic, were studied in healthy male subjects by comparing plasma concentrations and urinary excretion following intravenous, intramuscular, oral and rectal administration. Two oral dosage forms were studied: 10-mg tablets and a 10-mg/ml oral solution. The influence of a meal on the oral bioavailability and the dose-proportionality were also investigated. Plasma levels of intravenous domperidone could be described by a three-compartment model with a rapid distribution of 40% of the dose to a "shallow" peripheral compartment. The final elimination half-life was 7.5 hours. Peak plasma levels were reached within 30 minutes following intramuscular and oral administration and at 1-4 hours following rectal administration. Since domperidone showed an extensive first-pass elimination, AUC-values -a measure for the bioavailability- were considerably lower after oral than after parenteral administration. Equal oral and rectal doses gave a similar bioavailability. AUC-values increased proportionally with the dose over a 10-60 mg range. Cumulative urinary excretion of unchanged domperidone was proportional to corresponding AUC-values. The bioavailability was discussed in the light of the therapeutic results.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7250152     DOI: 10.1007/BF03189516

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  22 in total

1.  A double-blind crossover trial of domperidone in chronic postprandial dyspepsia.

Authors:  W Englert; D Schlich
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

2.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

3.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

4.  Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone.

Authors:  J M Van Nueten; C Ennis; L Helsen; P M Laduron; P A Janssen
Journal:  Life Sci       Date:  1978-08-07       Impact factor: 5.037

5.  On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man.

Authors:  W Meuldermans; R Hurkmans; E Swysen; J Hendrickx; M Michiels; W Lauwers; J Heykants
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

6.  3H-Domperidone: a selective ligand for dopamine receptors.

Authors:  M Baudry; M P Martres; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-09       Impact factor: 3.000

7.  Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting.

Authors:  A J Reyntjens; C J Niemegeers; J M Van Nueten; P Laduron; J Heykants; K H Schellekens; R Marsboom; A Jageneau; A Broekaert; P A Janssen
Journal:  Arzneimittelforschung       Date:  1978

8.  A multicentre pilot study of parenteral and rectal administration of domperidone in the treatment of severe vomiting in children.

Authors:  R Clara; J Van Hollebeke; E Heck
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

9.  Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying.

Authors:  A Bekhti; L Rutgeerts
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

10.  Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry.

Authors:  T R Weihrauch; C F Förster; J Krieglstein
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

View more
  25 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

2.  Domperidone for lactating women.

Authors:  Orlando P da Silva; David C Knoppert
Journal:  CMAJ       Date:  2004-09-28       Impact factor: 8.262

Review 3.  Biowaivers for oral immediate-release products: implications of linear pharmacokinetics.

Authors:  Fried Faassen; Herman Vromans
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

5.  Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial.

Authors:  O P da Silva; D C Knoppert; M M Angelini; P A Forret
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

6.  On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats.

Authors:  J Heykants; A Knaeps; W Meuldermans; M Michiels
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

7.  On the pharmacokinetics of domperidone in animals and man II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat.

Authors:  M Michiels; R Hendriks; J Heykants
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

8.  Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro.

Authors:  Bryan A Ward; Alan Morocho; Abdullah Kandil; Raymond E Galinsky; David A Flockhart; Zeruesenay Desta
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

9.  Predicting new molecular targets for known drugs.

Authors:  Michael J Keiser; Vincent Setola; John J Irwin; Christian Laggner; Atheir I Abbas; Sandra J Hufeisen; Niels H Jensen; Michael B Kuijer; Roberto C Matos; Thuy B Tran; Ryan Whaley; Richard A Glennon; Jérôme Hert; Kelan L H Thomas; Douglas D Edwards; Brian K Shoichet; Bryan L Roth
Journal:  Nature       Date:  2009-11-01       Impact factor: 49.962

Review 10.  Treatment of nausea and vomiting in terminally ill cancer patients.

Authors:  Paul A Glare; David Dunwoodie; Katherine Clark; Alicia Ward; Patsy Yates; Sharon Ryan; Janet R Hardy
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.